Although ETS2 was initially characterized as a proto-oncogene acute megakaryocytic leukemia (AMKL) [10], however, the clinical impact of ETS2 expression in AML remains unknown. This evidence concerns the gene ETS2 and acute megakaryoblastic leukemia.